|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Bilancio 2014 > Globale > Gruppo V > Esperimento RDH > Milestones**  Top of Form   |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | | Gruppo V | RDH | | **Milestones Proposte e Concordate** | | | | |  | | | | | | | | **Milestones Proposte** | |  | **Milestones Concordate** | | | | | **Data** | **Descrizione** |  | **Data** | **Descrizione** |  | Completamento | | **31-03-2014** | Nano-particles + glucose/FDG/RGD production |  | 31-03-2014 | DA NATT: Nano-particles + glucose/FDG/RGD production: |  | 0 | |  | | | | | | | | **30-06-2014** | WP2: Caratterizz. linea cellulare Daoy (Eff. di piastramento con e senza epotilone, curve di crescita). Determinazione concentr. epotilone per impiego con tre linee cellulari. |  | 30-06-2014 | WP2: Caratterizz. linea cellulare Daoy (Eff. di piastramento con e senza epotilone, curve di crescita). Determinazione concentr. epotilone per impiego con tre linee cellulari. <br> <br> |  | 0 | |  | | | | | | | | **30-06-2014** | Nano-particles radiolabelling |  | 30-06-2014 | DA NATT: Nano-particles radiolabelling |  | 0 | |  | | | | | | | | **31-12-2014** | Milestone aggiuntiva (11-10-2013 11:39:08) |  | 31-07-2014 | WP2: Completamento campagna di misure di radiobilogia iniziate in TPS e roseguite in RDH. |  | 0 | |  | | | | | | | | **30-09-2014** | Scout tests on small animals |  | 30-09-2014 | DA NATT: Nano-particles radiolabelling Scout tests on small animals: |  | 0 | |  | | | | | | | | **31-12-2014** | WP1: Raffinamento e completamento del TPS (interfaccia e modellistica) per una sua inclusione in un workflow clinico (pianificazione trattamenti e QA) e di ricerca. |  | 31-12-2014 | WP1: Raffinamento e completamento del TPS (interfaccia e modellistica) per una sua inclusione in un workflow clinico (pianificazione trattamenti e QA) e di ricerca. <br> <br> |  | 0 | |  | | | | | | | | **31-12-2014** | WP2: Primi esperimenti con fotoni per determinazione delle curve di sopravvivenza con e senza epotilone per la linea Daoy e primi esperimenti con protoni per la misura delle curve di sopravvivenza con e senza epotilone per le linee A549 e U373 e Daoy. |  | 31-12-2014 | WP2: Primi esperimenti con fotoni per determinazione delle curve di sopravvivenza con e senza epotilone per la linea Daoy e primi esperimenti con protoni per la misura delle curve di sopravvivenza con e senza epotilone per le linee A549 e U373 e Daoy. <br> <br> |  | 0 | |  | | | | | | | | **31-12-2014** | WP3: realizzazione e test beam sotto fascio del prototipo pCT ad area estesa (5x20cm2) composto da un piano x-y più calorimetro |  | 31-12-2014 | WP3: realizzazione e test beam sotto fascio del prototipo pCT ad area estesa (5x20cm2) composto da un piano x-y più calorimetro <br> <br> |  | 0 | |  | | | | | | | | **31-12-2014** | WP4: Realizzazione prototipo in scala ridotta di rivelatore di range residuo con tracciatori integrati e nuova elettronica di front-end e read-out |  | 31-12-2014 | WP4: Realizzazione prototipo in scala ridotta di rivelatore di range residuo con tracciatori integrati e nuova elettronica di front-end e read-out <br> <br> |  | 0 | |  | | | | | | | | **31-12-2014** | WP5 Caratterizzazione e tests del primo piano del tracciatore |  | 31-12-2014 | WP5 Caratterizzazione e tests del primo piano del tracciatore <br> <br> |  | 0 | |  | | | | | | | | **31-12-2014** | WP6: Completamento della misura delle sezioni d\_urto doppio differenziali per frammenti fino a 45 gradi |  | 31-12-2014 | WP6: Completamento della misura delle sezioni d\_urto doppio differenziali per frammenti fino a 45 gradi <br> <br> |  | 0 | |  | | | | | | | | **31-12-2014** | WP7: Sottomissione del chip TERA per alte correnti. |  | 31-12-2014 | WP7: Sottomissione del chip TERA per alte correnti. <br> <br> |  | 0 | |  | | | | | | | | **31-12-2014** | WP5: Caratterizzazione e tests del prototipo PET ( 9vs9) sia con sorgenti sia con ioni |  | 31-12-2014 | WP5: Caratterizzazione e tests del prototipo PET ( 9vs9) sia con sorgenti sia con ioni <br> <br> |  | 0 | |  | | | | | | | | **31-12-2014** | WP5: Assessment performance modulo SiPM ed elettronica di acquisizione ai rate clinici del fascio CNAO |  | 31-12-2014 | WP5: Assessment performance modulo SiPM ed elettronica di acquisizione ai rate clinici del fascio CNAO <br> <br> |  | 0 | |  | | | | | | | | **31-12-2014** | WP8: Progettazione del sistema di launching per sorgenti di tipo ECRIS al fine di consentire la plasma ignition con conversione modale |  | 31-12-2014 | WP8: Progettazione del sistema di launching per sorgenti di tipo ECRIS al fine di consentire la plasma ignition con conversione modale <br> <br> |  | 0 | |  | | | | | | | | **31-12-2014** | WP8: Esperimento con diverse configurazioni di launching dell\_onda elettromagnetica per incrementare l'efficienza di conversione modale nella plasma trap; |  | 31-12-2014 | WP8: Esperimento con diverse configurazioni di launching dell\_onda elettromagnetica per incrementare l'efficienza di conversione modale nella plasma trap; <br> <br> |  | 0 | |  | | | | | | | | **31-12-2014** | Milestone aggiuntiva (11-10-2013 11:37:09) |  | 31-12-2014 | WP1: Utilizzazione di dati provenienti dal WP2 (campagna di misure cominciata in TPS e proseguita in RDH) all'interno del KTPS. |  | 0 | |  | | | | | | | | **31-12-2014** | Milestone aggiuntiva (11-10-2013 12:20:34) |  | 31-12-2014 | DA NATT: MC simulations with cells loaded with GNPs of different size |  | 0 | |  | | | | | | | |  | | | | | | |   Bottom of Form |